Phase 2a Study of VTX3232 in Parkinson's Disease

NCT06556173 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson Disease

Interventions

DRUG: VTX3232

Sponsor

Zomagen Biosciences Ltd.